Navigation Links
Derma Sciences Reports Fourth Quarter, Year-End Results for 2008
Date:4/1/2009

PRINCETON, N.J., April 1 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, reported that sales for 2008 rose 47.1% year-over-year, reflecting incremental sales from its First Aid Division (FAD) and higher sales of proprietary advanced wound care products led by MEDIHONEY(R). Sales for the year were $50.2 million vs $34.1 million in 2007. The Company's loss increased consistent with expectations to $4.0 million or $0.10 per share, compared to 2007's loss of $2.3 million or $0.09 per share, as Derma Sciences implemented its advanced wound care growth strategy, integrated FAD into the company and continued its investment in R&D. Fourth quarter 2008 sales were $12.6 million versus $10.7 million in 2007. Net losses diminished each quarter during the year, and the 2008 fourth quarter loss was $0.6 million versus $2.0 million in 2007.

Chairman and CEO Ed Quilty commented, "Our advanced wound care products made great strides in 2008. Sales for our silver alginate product, ALGICELL(R) Ag, nearly doubled to over $1.1 million. Sales of our MEDIHONEY product, launched in October 2007, grew consistently each quarter, and ended the year at $1.5 million in 2008 versus $0.1 million for the final three months of 2007. MEDIHONEY continues to get great media coverage, typified by a cluster of television and print articles reporting that the product was credited for saving a patient's leg from having to be amputated at Long Island Jewish Hospital in January 2009. Its coverage in medical journals continues to be strong, as seven separate articles on the emerging use of MEDIHONEY were published in the major wound care journals since December of 2008.

"In the fourth quarter and early 2009, we launched three additional promising new products," Quilty stated. "Our prop
'/>"/>

SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Derma Sciences to Report 2008 Fourth Quarter and Year-End Results on April 1, 2009
2. Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced
3. Wendy E. Roberts, MD, Named 2009-2010 President of the Womens Dermatologic Society
4. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
5. Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting
6. Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting
7. The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection
8. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
9. Professional Skin Care Company OrthoNeutrogena Becomes Ortho Dermatologics
10. American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies
11. Derma Sciences Gains FDA Clearance for Novel BIOGUARD(TM) Barrier Dressing with NIMBUS(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013 GS1 has honored Tim ... Company, and Danny Wegman, CEO, Wegmans Food Markets, ... General Assembly and Global Leadership Summit, held May 20-23 ... were recognized for their outstanding contributions to the advancement ... used supply chain standards globally. , “The leadership, ...
(Date:5/22/2013)... and teens exposed to radiation during CT scans are ... a large, long-term study. The risks, however, are ... who each had one CT scan, only about six ... years, according to researchers from Australia and Europe. ... to patients when making decisions about CT (computed tomography) ...
(Date:5/22/2013)... This news release is available in German . ... Forschungsgemeinschaft (DFG, German Research Foundation) is establishing 11 new ... in Germany. This decision was made by the relevant ... euros has been awarded to the new programmes for ... In addition to the 11 new Research Training Groups, ...
(Date:5/22/2013)... to finish the last ounce in their bottle might be ... burn off, a bad habit remains. , Brigham Young University ... obesity at 24 months of age strongly traces back to ... it puts you on a trajectory where you are likely ... an adult," said Forste. "That,s a big concern." , The ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal ... the previous version used prior to 2010, the 7-valent ... study published today in Vaccine . , The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
Breaking Medicine News(10 mins):Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Children Who Have CT Scans May Face Higher Cancer Risk 2Health News:DFG establishes 11 new research training groups 2Health News:DFG establishes 11 new research training groups 3Health News:DFG establishes 11 new research training groups 4Health News:DFG establishes 11 new research training groups 5Health News:Overeating learned in infancy, study suggests 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
... a leading global clinical,research organization, is pleased to ... at the JCAHPO annual continuing education,program. Diana who ... Cannula, worked in ophthalmic practice for several years,prior ... (CRA). The,meeting will take place in New Orleans, ...
... 1 The makers of the WaveSense line ... Claudio,Carboni, formerly of Menarini Diagnostics, has joined as ... WaveSense Europe will,distribute the company,s high accuracy, WaveSense ... market both directly and through local,partners. Carboni ...
... MINNEAPOLIS /ST. PAUL (October 31, 2007) According to new ... information in most cases to apply a policy and ... the information. Medicare appears reluctant to aggressively enforce ... are inconsistent with scientific evidence. , By law, Medicare ...
... Video Component Enables Users to Upload Video Confessions/ ... on newfaceofresearch.com for Peer-to-Peer Viewing, PHILADELPHIA and ... Thomson Corporation (NYSE: TOC ; TSX: TOC) ... research and,business communities, today announced the launch of ...
... providing all current services, invest $20 million in ... ... Calif., Oct. 31 Prime Healthcare Services,Inc. (PHS), the owner ... today that Prime Healthcare Centinela, one,of its subsidiaries, has acquired ...
... Health,Services (MHS), a not-for-profit health care system with ... that it has selected,Integrated Healthcare Holdings, Inc. (IHHI) ... a partially physician-owned publicly traded hospital management,company, owns ... a total of,770 beds, 2787 employees and 1725 ...
Cached Medicine News:Health News:Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting 2Health News:Ex-Head of Menarini Diabetes Unit Launches WaveSense Europe 2Health News:U of M study: Medicare lacks tools, incentives to enforce evidence-based coverage policies 2Health News:Thomson Scientific Launches 'Confessions ... of a User' Campaign Asking 'Are You the New Face of Research?' 2Health News:Prime Healthcare Services Acquires Centinela Hospital Medical Center 2Health News:Prime Healthcare Services Acquires Centinela Hospital Medical Center 3Health News:Prime Healthcare Services Acquires Centinela Hospital Medical Center 4Health News:Memorial Health Services Announces Sale of Anaheim Memorial Medical Center 2
(Date:5/22/2013)... , May 22, 2013  Avanir Pharmaceuticals, Inc. (NASDAQ: ... present an overview of the company at the following conferences. ... , Presentation date: Wednesday May 29, 2013 , ... 2013 Global Healthcare Conference , Presentation date: Wednesday June ... A live webcast and 30-day ...
(Date:5/22/2013)... Mass. , May 22, 2013  Flagship ... firm focused on healthcare and sustainability, today announced ... as a Senior Partner. In this role, ... to portfolio companies. In addition to ... Mr. Bancel also serves as President and Chief ...
(Date:5/22/2013)... , May 22, 2013  Grifols, a global ... , presented results from a study demonstrating that a ... Inhibitor [Human]) increased levels of the alpha 1 ... to levels that are considered within the normal range ... condition in which low levels of the alpha 1 ...
Breaking Medicine Technology:Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4
... Elusys Therapeutics, Inc.,(Elusys), a privately held biopharmaceutical ... life-threatening infectious,diseases, today announced it has been ... development of Anthim(TM), the company,s late-stage anthrax,therapeutic. ... or in part with Federal,funds from the ...
... Trial Aims to Treat Renal Artery Obstructions and Lower ... Pressure in Patients Not Responding to Medication, ... today announced enrollment of the first patient in HERCULES ... and,Safety), a U.S. clinical trial designed to evaluate the ...
Cached Medicine Technology:Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic 2Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis 2Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis 3
Castroviejo microscopic needle holder...
Dilator...
Microscopic scissors, curved...
Microscopic needle holder, curved...
Medicine Products: